Ovid Therapeutics has filed a patent for the use of allosteric modulators and/or gaboxadol to treat epileptic disorders. The patent specifically claims a method of treating Lennox-Gastaut syndrome by administering ganaxolone or a pharmaceutically acceptable salt thereof as an oral suspension. GlobalData’s report on Ovid Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ovid Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Ovid Therapeutics's grant share as of September 2023 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of lennox-gastaut syndrome using ganaxolone oral suspension
A recently filed patent (Publication Number: US20230293501A1) describes a method for treating Lennox-Gastaut syndrome, a severe form of epilepsy. The method involves administering a pharmaceutical composition containing ganaxolone or a pharmaceutically acceptable salt thereof as an oral suspension.
The patent claims specify various aspects of the method. Claim 2 states that the pharmaceutical composition should provide an in vivo plasma profile with a maximum concentration (Cmax) of ganaxolone in the blood of less than about 500 ng/ml. Claim 3 further specifies a Cmax of less than about 200 ng/ml. Claim 4 focuses on the area under the curve (AUC) of the plasma profile, stating that it should be less than about 900 ng hr/ml.
Claim 5 combines the requirements of both Cmax and AUC, stating that the pharmaceutical composition should have a Cmax of less than about 500 ng/ml and an AUC of less than about 900 ng hr/ml.
Claims 6 and 7 address the duration of symptom improvement after administration of the pharmaceutical composition. Claim 6 states that the patient should experience improvement in at least one symptom for more than 4 hours, while claim 7 extends this duration to more than 8 hours.
Claims 8, 9, and 10 discuss the dosing frequency and amount of ganaxolone administered. Claim 8 states that the patient can be administered ganaxolone once daily or twice daily, while claim 9 specifies three times daily. Claim 10 sets an upper limit of up to 1,800 mg/day for the amount of ganaxolone administered.
Claims 11 to 30 provide specific dosage options for ganaxolone, ranging from 50 mg to 1,050 mg/day.
Lastly, claim 20 highlights the intended therapeutic effect of the pharmaceutical composition, which is the reduction in the frequency and severity of seizures associated with Lennox-Gastaut syndrome.
In summary, the patent describes a method for treating Lennox-Gastaut syndrome using an oral suspension of ganaxolone or a pharmaceutically acceptable salt thereof. The method aims to achieve specific plasma profiles of ganaxolone, provide symptom improvement for a certain duration, and reduce the frequency and severity of seizures. Various dosage options are also provided in the patent.
To know more about GlobalData’s detailed insights on Ovid Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
